Evicenter
MarkdownMedical informationP&T meetings
Tirabrutinib

Primary central nervous system lymphoma

Last updated
67 sources

Section 6 of 6

References

67 sources

  1. Akimoto et al. (2026) (opens in a new tab)
  2. Arakawa et al. (2023) (opens in a new tab)
  3. Cayman Chemical safety data sheet (2025) (opens in a new tab)
  4. Čermáková et al. (2025) (opens in a new tab)
  5. Chen et al. (2022) (opens in a new tab)
  6. Deciphera Pharmaceuticals (opens in a new tab)
  7. Deciphera Pharmaceuticals (2026) (opens in a new tab)
  8. Dhillon (2020) (opens in a new tab)
  9. Doolittle et al. (2013) (opens in a new tab)
  10. FDA Orphan Drug Designations and Approvals (2023) (opens in a new tab)
  11. Ferreri et al. (2024) (opens in a new tab)
  12. Gilead Sciences protocol GS-US-401-2076 (2019) (opens in a new tab)
  13. Guo et al. (2024) (opens in a new tab)
  14. Hoang-Xuan et al. (2023) (opens in a new tab)
  15. Hsiao et al. (2026a) (opens in a new tab)
  16. Hsiao et al. (2026b) (opens in a new tab)
  17. Iizuka-Honma et al. (2023) (opens in a new tab)
  18. Ikegawa et al. (2025) (opens in a new tab)
  19. Ishi et al. (2025) (opens in a new tab)
  20. Kawabata et al. (2026) (opens in a new tab)
  21. Kawasaki et al. (2025) (opens in a new tab)
  22. Kawauchi et al. (2025) (opens in a new tab)
  23. KEGG (opens in a new tab)
  24. Khairunnisa et al. (2024) (opens in a new tab)
  25. Kitamura and Kuyama (2022) (opens in a new tab)
  26. Kozaki et al. (2023) (opens in a new tab)
  27. Liao et al. (2024) (opens in a new tab)
  28. Liclican et al. (2020) (opens in a new tab)
  29. Lv et al. (2022) (opens in a new tab)
  30. Matsunuma et al. (2026) (opens in a new tab)
  31. Meng et al. (2022) (opens in a new tab)
  32. Motomura et al. (2024) (opens in a new tab)
  33. Nagane et al. (2024) (opens in a new tab)
  34. Nakagawa et al. (2022) (opens in a new tab)
  35. Narita et al. (2021) (opens in a new tab)
  36. National Cancer Institute Drug Dictionary (opens in a new tab)
  37. National Cancer Institute NCI-2021-14196 (opens in a new tab)
  38. National Cancer Institute PDQ health professional version (opens in a new tab)
  39. National Cancer Institute PDQ patient version (opens in a new tab)
  40. Nayak et al. (2025a) (opens in a new tab)
  41. Nayak et al. (2025b) (opens in a new tab)
  42. Nayak et al. (2026) (opens in a new tab)
  43. Okawara et al. (2025) (opens in a new tab)
  44. Okita et al. (2021) (opens in a new tab)
  45. Ono et al. (2026) (opens in a new tab)
  46. ONO Pharma and Deciphera Pharmaceuticals (2025) (opens in a new tab)
  47. ONO Pharma USA (2023) (opens in a new tab)
  48. ONO Pharma USA (2025) (opens in a new tab)
  49. Ono Pharmaceutical (2026) (opens in a new tab)
  50. Ono Pharmaceutical corrected ROSETTA data notice (opens in a new tab)
  51. Ono Pharmaceutical corrected ROSETTA real-world progression-free survival figure (opens in a new tab)
  52. Ono Pharmaceutical second quarter results presentation script (2026) (opens in a new tab)
  53. PMDA review report (2020) (opens in a new tab)
  54. PMDA revision of precautions (2024) (opens in a new tab)
  55. PROSPECT study website (opens in a new tab)
  56. Taiwan Food and Drug Administration assessment report (opens in a new tab)
  57. Tan et al. (2025) (opens in a new tab)
  58. University of California, Irvine (opens in a new tab)
  59. Wang et al. (2025) (opens in a new tab)
  60. Yamasaki et al. (2025a) (opens in a new tab)
  61. Yamasaki et al. (2025b) (opens in a new tab)
  62. Yashima et al. (2026) (opens in a new tab)
  63. Yasu et al. (2026) (opens in a new tab)
  64. Yonezawa et al. (2024) (opens in a new tab)
  65. Yoshioka et al. (2021) (opens in a new tab)
  66. Yoshioka et al. (2022) (opens in a new tab)
  67. Zhang et al. (2024) (opens in a new tab)